NCT02314351

Intravenous Metoclopramide in the Acute Treatment of Migraine: A Double-blind, Randomized, Placebo-controlled Trial

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 148 (actual)
• Sponsor: Kocaeli University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Migraine attacks were frequently diagnosed in the emergency departments. Also intravenous metoclopramide was a commonly used drug in the acute abortive treatment of migraine. However, the role of metoclopramide was based on three randomized, placebo-controlled studies, which were carried out with relatively few patients. Those trials suggested that metoclopramide produced larger improvements in visual analog scale (VAS) scores, however they revealed conflicting results and had significant methodological problems (risk of bias, allocation of concealment, intention-to-treat analysis). The investigators aimed to analyse the effects of intravenous metoclopramide in acute migraine attacks comparing with placebo.

Conditions

• Migraine Disorders

Interventions

Type	Name	Description
DRUG	Metoclopramide 10 mg	Intravenous form of metoclopramide is in the same appearance with placebo
DRUG	Placebo	Intravenous form of metoclopramide is in the same appearance with placebo
DRUG	Fentanyl	Intravenous fentanyl (1 mcg/kg), if pain persists at 30th minute

Timeline

• Start date: 2014-12-01
• Primary completion: 2017-01-01
• Completion: 2017-01-01
• First posted: 2014-12-11
• Last updated: 2017-01-04

Locations

1 site across 1 country: Turkey (Türkiye)